

Galileo Biotech Innovation Fund

Investing in the future of biotechnology

Market

The fund offers focused access to companies in the field of genome editing. Representing the next step in the evolution of medical technology, genome editing holds the potential to cure a variety of rare diseases but also offers a novel approach to more common conditions with established treatments. Further applications range from livestock to crop science.

Approach

We choose a thematic approach since we believe that estimating the success probabilities of individual companies in genome editing is heavily error prone and can lead to missed opportunities and cluster risks.

We aim to hold between 25 - 40 companies, providing us with exposure while offering enough diversification to accommodate for larger volatility associated with early-stage investments. Further, we believe this is the sweet spot to capitalize on the theme while staying focused.

We exclude companies where we see funding, balance sheet or governance issues.

There is no focus on a specific medical field, e.g. oncology, hematology etc. Furthermore, no limitations on upper or lower market capitalisations are in place.

Spotlight


HIV: Immune deficiency caused by the HI virus attacking T-cells on the basis of the active CCR5 gene. HIV immune individuals carry a mutation of the CCR5 gene. First studies show that altering the gene or shutting it down completely lead to positive results. Clinical studies are ongoing.

Organ donation: The shortage of organ donations lead to research using pig organs; so far with limited success. Genome editing, however, has shown first results in preventing auto-immune reactions and shutting down over 62 viral genes prevalent in pig organs which have the potential to infect human cells.

Consequently, there is a large growth opportunity not only in the rare disease space but also the potential to capture market share in already treatable diseases. While there is ample runway to expand revenue and profits, innovation leaders with successful products may become takeover targets for large pharma and biotech companies.

Genome editing

We view genome editing as an umbrella term encompassing gene therapy, cell therapy and gene editing. All approaches entail some form of altering genetic information through a variety of methods (e.g. TALENs, CRISPR, meganuclease etc.) in order to enable cells to perform a desired function.



Transfer-messenger RNA bound to a ribosome with elongation factor G and a transfer RNA.

Leukemia: A form of cancer which attacks the lymphatic system. Cell therapy showed promising results by altering T-cells and curing the patient.

Duchenne Muscular Dystrophoby: The genetic disorder leads to progressive muscle degeneration and weakness due to a mutation in the Dystrophin gene and therefore a lack of the protein Dystrophin. The illness often forces patients into the wheel chair at a young age. Untreated, life expectancy is rarely above 30. First studies with mice showed that the gene can be reactivated.

Team



Cyrill Plüss
Lead Portfolio Manager

Cyrill is engaged in portfolio management and the investment process at Bellecapital. His experience includes work in an M&A boutique with focus on specialty chemicals company transactions and in the finance department of Syngenta Europe. He last worked as Equity Research Analyst at Kepler Capital Markets in Zurich. At Kepler, he mainly covered Swiss technology stocks. He graduated from the University of St. Gallen (HSG) with a major in Finance.



Mathias Heim
CIO Bellecapital

Before joining Bellecapital, he worked as an investment manager for a hedge fund in Zurich. He has more than 18 years experience in capital markets. Former employers include UBS, LGT and Barclays Capital. He holds a Master degree from the University of St. Gallen (HSG) in Finance.



Xinyue Hou
Analyst

With China Hedge Fund working experience, Xinyue joined the firm's investment team part time following her Master's studies at the University of St. Gallen (HSG).



Disclaimer: For marketing and information purposes by Bellecapital Partners AG: The Galileo – Biotech Innovation Fund is a UCITS fund under Luxembourg law in the category “Securities Fund”. The fund may not be marketed, either directly or indirectly in the United States of America or be sold to US persons. The information in this document is given for information purposes only and does not qualify as an offer or as investment advice. No liability is assumed for the accuracy and completeness of the information. Opinions and assessments contained in this document may change and reflect the point of view of Bellecapital Partners AG in the current economic environment. This document qualifies as marketing material. Investments should only be made after a thorough reading of the current prospectus and/or the fund regulations, the Key Investor Information (KID), the current annual and semi-annual reports (the “legal documents”), as well as after consulting an independent finance specialist. Moreover, Bellecapital Partners AG strongly recommends that potential investors consult a tax specialist regarding the consequences of investments in the specific legislation of their tax liability. All documents are available on the website of IPConcept (fund administrator). The performance of past values and returns is no indicator of their current or future development. The performance of values and returns does not include the fees and costs which may be charged when buying, selling and/or switching units. This document is being provided to you in response to your specific request for information. Distributions of this document or disclosure of its contents to any person other than your advisors or representatives is prohibited.